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Abstract
We have previously described the generation of a novel Ebola virus (EBOV) vaccine platform based on (a) replication-
competent rabies virus (RABV), (b) replication-deficient RABV, or (c) chemically inactivated RABV expressing EBOV
glycoprotein (GP). Mouse studies demonstrated safety, immunogenicity, and protective efficacy of these live or inactivated
RABV/EBOV vaccines. Here, we evaluated these vaccines in nonhuman primates. Our results indicate that all three vaccines
do induce potent immune responses against both RABV and EBOV, while the protection of immunized animals against
EBOV was largely dependent on the quality of humoral immune response against EBOV GP. We also determined if the
induced antibodies against EBOV GP differ in their target, affinity, or the isotype. Our results show that IgG1-biased humoral
responses as well as high levels of GP-specific antibodies were beneficial for the control of EBOV infection after
immunization. These results further support the concept that a successful EBOV vaccine needs to induce strong antibodies
against EBOV. We also showed that a dual vaccine against RABV and filoviruses is achievable; therefore addressing concerns
for the marketability of this urgently needed vaccine.
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Introduction
Several members of the Ebolavirus genus and Marburgvirus genus,
Family Filoviridae, cause severe and often fatal viral hemorrhagic
fever in humans and nonhuman primates [1]. While the public
health burden of filovirus infections remains low relative to other
public health threats in Africa, outbreaks continue to affect the
Central African region including recent outbreaks in Uganda and
the Democratic Republic of the Congo in 2012. The high case
fatality rate, the increasing public health threat in Africa, and the
biodefense concerns associated with these viruses have resulted in
considerable activity in filovirus vaccine development [2,3].
Several vaccination strategies, including DNA, adenovirus,
recombinant vesicular stomatitis virus (rVSV), virus-like particles
(VLPs) and recombinant parainfluenza virus vectored vaccines,
have been developed to deliver primarily the EBOV glycoprotein
(GP) as antigen and have been shown to confer protection in
animal models [2,4–7]. While each vaccine strategy has shown
promising results and is protective in macaques, concerns such as
vaccine safety, preexisting vector immunity, manufacturing, or
lack of commercial interest have slowed progress.
Recent investigations have focused on the identification of
immune parameters that might serve as correlates of protection in
vaccinated nonhuman primates (NHPs). The majority of evidence
suggests that IgG antibody levels are important for protection in
immunized macaques (adenovirus or rVSV-vectored EBOV GP)
although the contribution of neutralizing antibodies to protection
is unclear [8,9]. Further support for the potential contribution of
antibodies to protection was recently provided by two studies
demonstrating that passive transfer of purified IgG from NHP
survivor sera or neutralizing monoclonal antibody cocktails could
confer protection from Ebola or Marburg virus infections [10,11].
In addition Marzi et. al. showed that the rVSV mechanism of
protection for EBOV is mediated by antibodies [12].
EBOV-specific cellular immune responses have also been
characterized after several immunization strategies including
DNA/adenovirus and VLPs [7]. Using T cell depletion experi-
ments, Sullivan et al. recently concluded that EBOV-specific CD8+
T cells and not humoral immunity mediated protection from
EBOV infection upon adenovirus/EBOV-GP immunization [13].
Collectively, these studies suggest that immune parameters that
correlate with and/or confer protection may be multi-factorial and
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vary by vaccination platform. However, we also need to consider
that there are likely different requirements for the induction of
anti-EBOV immunity and the recall response after exposure to the
pathogen. It is not likely that long-lived immunity can be achieved
without T-helper cells. In the case of GP-specific antibodies it
needs to be shown that they are maintained over time or CD4+ T
helper cells will be required to mount fast responses after infection.
A filovirus vaccine would be directed for use in humans at risk of
infection in Africa as well as for laboratory workers, healthcare
providers, first responders, soldiers, or travelers. Furthermore,
EBOV vaccines could be utilized in endangered wildlife species
such as gorillas and chimpanzees in Central Africa where they are
at risk of lethal EBOV disease. Epidemiologic studies have
indicated that EBOV outbreaks have resulted in numerous deaths
of these animals in Gabon and the Democratic Republic of
Congo, hindering conservation efforts to protect these populations
[14–16]. A vaccine to protect these at risk NHPs would have a
second critical benefit to humans. As EBOV is a zoonotic disease
with documented human outbreaks, which can arise from contact
with diseased NHPs [17], prevention of disease in these animals
might reduce the frequency of EBOV transmission into humans
resulting in reduced frequency of outbreaks.
Our goal is to identify a vaccine platform for EBOV and other
filoviruses of public health importance that would (a) produce
promising candidates for use in both humans and endangered
wildlife species and (b) yield multiple vaccine candidates increasing
the likelihood that an optimal balance between reactogenicity and
immunogenicity might be achieved. To this end, we have utilized
the rabies virus (RABV) vaccine platform to develop (a)
replication-competent, (b) replication-deficient, and (c) chemically
inactivated vaccines expressing EBOV GP (strain Mayinga) [18].
As RABV is still a considerable public health issue in Africa with
an estimated 24,000 deaths reported yearly [19–21], a bivalent
vaccine that confers protection from RABV and EBOV would be
an economical and efficient public health tool. The RABV vaccine
platform has proven to be an excellent vaccine vector for safe
induction of immunity to HIV, SARS-CoV, and hepatitis C virus
[22–26]. Further attenuated RABV-vectored vaccines have been
generated by the deletion of the RABV glycoprotein (G) gene and
propagation of viruses on trans-complementing cell lines that
express RABV G [25,27,28]. Additionally, beta-propiolactone-
mediated inactivation of RABV-vectored vaccines has been used
to generate killed vaccine candidates against hepatitis C virus and
bacillus anthracis with optimal safety profiles [22,29]. Our primary
focus is the development of an inactivated vaccine for use in
humans based on the potential for superior safety and the
successful history of the existing beta propiolactone-inactivated
RABV vaccine that is widely used in humans. However, in
addition to the development of inactivated RABV/EBOV
vaccines, the parental recombinant RABV vaccine used to
generate the RABV/EBOV vaccine candidates is derived from
the SAD B19 strain which is used for wildlife vaccination by
baiting in Europe suggesting additional applications of our vaccine
candidates [30,31]. Therefore, live attenuated RABV/EBOV
vaccines could be considered for use in Africa in an analogous
campaign to protect at risk NHPs from lethal EBOV infections.
Results
Immunogenicity of RABV-based vaccines in NHPs
Our previous research with RABV-based vaccine vectors
expressing HIV-1 antigens indicated that such vaccines are highly
immunogenic in NHPs against both the RABV-based vector and
foreign antigens [25,32]. However, only replication-competent
vaccine vectors expressing HIV-1 GagPol or Env have been
analyzed in NHPs, and immunogenicity against filovirus antigens
expressed in the RABV vector needs to be evaluated in the NHP
model. Here, we analyzed the immunogenicity of three different
RABV/EBOV vaccine vectors in NHPs, namely replication-
competent (BNSP333-GP), replication-deficient (BNSPDG-GP)
and inactivated virions (INAC-BNSP333-GP) expressing or
carrying EBOV GP. The empty, replication-competent vector
(BNSP333) served as a control (Figure 1A, [18]).
As outlined in the immunization schedule in Figure 1B, four
groups of rhesus macaques were immunized intramuscularly (i.m.)
in the caudal thigh muscle as follows: group 1, three NHPs, 56107
focus-forming units (FFU) BNSP333, black; group 2, four NHPs,
56107 FFU BNSP333-GP, red; group 3, four NHPs, 16107 FFU
BNSPDG-GP, blue; group 4, four NHPs, 250 mg purified INAC-
BNSP333-GP, green. We followed the immune response of the
vaccinated animals over time after vaccination as well as after
challenge (Figure 1B). Notably, the goal of this novel vaccine
approach was to develop a vaccine that protects from two different
highly lethal diseases, rabies and filovirus induced hemorrhagic
fever. Therefore, we followed both RABV and EBOV GP-specific
immune responses. As shown in Figure 2A, all three vaccines and
the empty control vector induced seroconversion against RABV G
as early as day 7 after immunization, with increasing IgG levels at
day 14 and slightly decreasing levels for the sera collected at day
28. In contrast, at day 7, EBOV GP-specific humoral responses
were only detected in sera from animals vaccinated with the
replication-deficient vaccine (Figure 2B). On day 14, all groups
(groups 2–4) showed a positive signal in the EBOV GP-specific
ELISA whereas for the control animals (group 1) only background
signals were detected (Figure 2B). Interestingly, the replication-
deficient (RABV G-deleted) vector expressing EBOV GP induced
the highest EBOV GP-specific responses but the lowest RABV G
responses. This is most likely due to the fact that this virus does not
encode RABV G and the RABV G-specific immune response
results from the G protein contained in the initial vaccine particle
preparation [27]. Our previous research on live RABV-based
Author Summary
Ebola virus (EBOV) has been associated with outbreaks in
human and nonhuman primate populations since 1976.
With a fatality rate approaching 90%, EBOV is one of the
most lethal infectious diseases in humans. The increased
frequency of EBOV outbreaks along with its potential to be
used as a bioterrorism agent has dramatically strength-
ened filovirus vaccine research and development. While
there are currently no approved vaccines or post exposure
treatments available for human use, several vaccine
candidates have shown to protect nonhuman primates
from lethal EBOV challenge. Our primary focus is to
develop vaccine candidates to protect humans and
endangered wildlife species at risk of infection in Africa.
Here, we evaluated the efficacy and immunogenicity of
our dual vaccines against EBOV and rabies virus (RABV) in
rhesus macaques. Our live replication-competent vaccine
provided 100% protection following EBOV challenge while
the replication-deficient and inactivated candidates pro-
vided 50% protection. Interestingly, protection is depen-
dent on the quality of the antibodies rather than the
quantity. All three RABV-based EBOV vaccines did induce
antibody levels necessary for protection from RABV
infection. These results encourage the further develop-
ment of these novel dual vaccines directed against two of
the most lethal viral diseases.
Antibodies and Rabies/Ebola Vaccine Platform
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vaccines indicated that pre-existing anti-RABV antibodies prevent
a successful secondary immunization; therefore, only the group of
rhesus macaques primed with the inactivated RABV virions
containing EBOV GP received a boost at day 28 with the same
vaccine (Figure 1B). The boost increased the humoral responses
against EBOV GP as well as RABV G for group 4 significantly
(Figure 2A and B, day 35 and 42). Remarkably, even the animals
that were not boosted showed an increase in humoral responses
directed against RABV G and EBOV GP from days 28 to 35, indi-
cating that the vaccines were still stimulating the immune system.
High ELISA titers of anti-RABV G antibodies are predictive of
protection of the immunized host, but we still wanted to confirm
the humoral response against RABV by virus neutralization assays
(VNA). The result presented in Figure 2C indicates that all four
vaccines induced virus-neutralizing antibodies as early as 7 days
after immunization. Notably, the VNA titers were well above the
critical level of 0.5 international units (I.U.), which is considered
protective from RABV infection in humans [33]. Similar to the
total IgG levels against RABV G, we detected an increase of the
RABV-specific immune responses by VNA for all vaccine groups.
In contrast to RABV, we were unable to detect significant levels of
virus-neutralizing antibodies directed against EBOV for groups 2–
4 compared to the controls of group 1 (data not shown). We also
analyzed the cellular responses utilizing an IFN-c specific ELI-
SPOT from larger blood samples collected at day 14 and 42. As
shown in Table 1, animals of the control group did not mount any
cellular responses when stimulated with EBOV GP-specific
peptide pools. The highest responses were detected for animals
immunized with the replication-competent vaccine, followed by
the replication-deficient and the killed viral particles at day 14.
However, in each group we failed to detect cellular responses in
one or two animals. At day 42, cellular responses were only
detected in two animals, which previously had the highest
responses. All other animals showed only a background level of
EBOV GP-specific cellular responses.
Outcome of challenge with EBOV in vaccinated animals
After day 42, all animals were transferred to the NIAID BSL-4
facility at the Rocky Mountain Laboratories for EBOV challenge.
Since the challenge virus stock had never been utilized in rhesus
macaques, we infected two of the three control animals (NHP1
and NHP2) on day 56 with 1000 PFU of EBOV (strain Mayinga)
prior to the other animals to ensure the pathogenicity of the virus
stock. NHP1 and NHP2 rapidly developed disease and reached
Figure 1. Immunization schedule and RABV/EBOV vaccine constructs. (A) Schematic of the RABV vaccine constructs expressing EBOV GP
used for prime and boost immunizations. (B) Experimental timeline: All NHPs were immunized on day 0 and challenged intramuscularly with
1,000 PFU of EBOV on day 56 or 70 as described in the Materials and Methods. The day of challenge (day 56 or 70) is referred to throughout the paper
as challenge day 0. Group 4 was boosted with 250 mg of the inactivated construct on day 28.
doi:10.1371/journal.ppat.1003389.g001
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the hemorrhagic state (rash) on day 6 and 7 post challenge,
respectively, at which point animals had to be euthanized
according to approved protocol. Based on this finding, we infected
the remaining 13 animals on day 70 with the same challenge virus
stock and dose. For each challenge experiment, physical exams
and blood draws were performed at day 0, 3, 6, 12, 16, 22, and 28
post-challenge. The outcome of the EBOV challenge and the
clinical findings are presented in Figure 3. As show in Figure 3A,
all animals immunized with the live replication-competent vaccine,
BNSP333-GP (group 2), survived the challenge. As expected, all
animals in the control group (NHP 1–3) had to be humanely
euthanized according to approved protocol mainly based on high
viremia at day 6 (Figure 3C) and rash. Two of four animals from
group 3, which were immunized with the replication-deficient
vaccine (NHP8 and NHP9), and two of four animals from group 4,
which received the inactivated RABV/EBOV particles (NHP14
Figure 2. Humoral immune response to RABV G and EBOV GP before Ebola Zaire challenge. (A) Rhesus macaque total IgG immune
response to RABV G. OD490 readings were compared to a World Health Organization (WHO) standard (human sera) for rabies. (B) Rhesus macaque
total IgG immune response to EBOV GP compared to a control macaque which survived EBOV infection. All sera were diluted 1:50 and analyzed in a 3
fold serial dilution via ELISA. (C) Neutralization assay for RABV G post immunization.
doi:10.1371/journal.ppat.1003389.g002
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and NHP15), had to be euthanized. The viral loads detected in the
blood of these animals (NHP8, NHP9, NHP14 and NHP15) did
not differ from those of the three control animals NHP1-3
(Figure 3C). Interestingly, five out of the twelve animals (NHP4,
NHP5, NHP6, NHP11 and NHP12) controlled challenge virus
replication with undetectable viremia, whereas for three animals
(NHP7, NHP10 and NHP13) the challenge virus was detected
transiently at one (group 2 and 3) or two time points (group 4)
(Figure 3C). The lack of protection was also reflected clinically
(Figure 3B, D–F). Animal body temperature, on average, increased
within the first few days after challenge but returned to the original
temperatures near day 12 post challenge (Figure 3B). Platelet count
significantly decreased after challenge for the unprotected animals
whereas protected animals regained normal platelet levels by day
12 post challenge (Figure 3D). Serum alanine aminotransferase
(ALT) (Figure 3E) and serum aspartate aminotransferase (AST)
levels (Figure 3F) monitored liver function. Elevated levels, as seen
by days 3–6, indicated liver damage as a result of EBOV infection.
Immune responses detected after challenge
We also monitored the immune responses of vaccinated animals
after challenge during the acute and convalescent phases of
disease. As shown in Figure 4, the three animals of the control
group failed to mount any EBOV GP-specific responses during the
course of the EBOV infection. In contrast, all three groups of
vaccinated NHPs (groups 2, 3 and 4) had similar levels of anti-
EBOV GP antibodies at the day of challenge (Figure 4A, challenge
day 0). The EBOV GP-specific antibodies remained at these levels
3 days after challenge (Figure 4B, challenge day 3). Interestingly, a
rapid increase to high levels of EBOV GP-specific IgG was
observed on day 6 after challenge in the serum of the five animals
that survived (NHP4, NHP5, NHP6, NHP11, and NHP12).
Notably, these high antibody levels were detected in those animals
that did not have detectable levels of EBOV RNA in their blood
during the course of challenge. The three animals (NHP7,
NHP10, and NHP13), which did show a lower but significant
increase in EBOV GP-specific antibodies 6 days after challenge,
demonstrated transient levels of EBOV viremia but survived
(figure 3C). Lastly, we failed to detect an increase in the humoral
responses against EBOV GP in the serum of four animals on day 6
post challenge (NHP8, NHP9, NHP14, and NHP15). These were
the animals that had to be humanely euthanized. Based on these
results, we concluded that one requirement for a successful RABV-
based EBOV vaccine is the rapid recall response of humoral
immunity against EBOV GP after EBOV challenge. The results
presented above also indicate that virus specific antibodies are
important to control EBOV infection. However, the antibody
titers against EBOV GP at the day of challenge were similar for all
three groups and, more importantly, the same within groups 3 and
4 where two animals in each group were protected while the other
two were not. Therefore, we decided to analyze the humoral
immune responses in greater detail.
First, we performed an EBOV GP specific ELISA utilizing full-
length EBOV GP as well as a ‘‘mucin-like domain’’ (MLD) deleted
version (EBOV GP-DMLD). The MLD is a heavily glycosylated
region of the EBOV GP ectodomain. Previous research indicates
that antibodies directed against the MLD not only fail to
neutralize EBOV but can even enhance the infection [34]. Results
shown in Figure 5 demonstrate that similar humoral responses
were detected for sera from all animals utilizing both full-length
EBOV GP (Figure 5A) and EBOV GP-DMLD (Figure 5B)
ELISAs. We concluded from these findings that there are no
significant differences in the target of the induced antibodies for
these three vaccines, at least not in regard to the MLD.
As there seem to be no obvious differences in the EBOV GP-
target of the antibodies within the different groups of vaccines, we
analyzed qualitative differences of the antibodies. Th1 dependent
IgG1 antibodies in NHPs have been shown to possess better
antiviral properties by mediating antibody-dependent cellular
cytotoxicity and complement activation [35]. Therefore, we
performed an isotype-specific ELISA utilizing full-length EBOV
GP to determine if any differences in the antibody isotypes
occurred between the vaccines. As shown in Figure 6, the positive
control NHP ratio of IgG2/IgG1 on day 0 post-challenge was
around 1.0, whereas this ratio was an average of about 2.0 for all
the vaccinated animals from groups 2–4. However, six days after
challenge this IgG2/IgG1 ratio changed to ,1.0 for the sera
collected for the animals from group 2, which is the group where
Table 1. ELISPOT GP response on frozen cells (spots per million cells).
Group NHP ID Sex Day 14 Day 42 Challenge Day 0 Challenge Day 6
BNSP333 1 F 0.0 0.5 75.0 6.7
2 M 7.5 0.0 138.3 44.7
3 F 0.0 0.0 258.3 78.3
BNSP333-GP 4 F 402.5 36.5 963.3 5565.0
5 M 1112.5 206.0 3261.7 6218.3
6 F 12.5 2.5 70.0 3668.3
7 M 95.0 0.5 35.0 5251.7
BNSPDG-GP 8 F 80.0 1.5 105.0 3.3
9 M 52.9 1.5 0.0 0.0
10 M 257.1 5.0 120.0 6551.7
11 F 165.7 0.5 525.0 6183.3
INAC-BNSP333-GP 12 M 54.3 4.5 248.3 5903.3
13 M 50.0 0.0 136.7 856.7
14 F 2.9 0.5 140.0 55.0
15 F 51.4 2.5 191.7 60.0
doi:10.1371/journal.ppat.1003389.t001
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all four animals survived. In contrast, the average of the IgG2/
IgG1 ratio for group 3 was 2.0 and for group 4 was 1.5. In both of
these groups two animals were not protected. These data suggest
that IgG1-biased humoral responses might be beneficial for the
control of EBOV infection. This contention was further supported
by the analysis of the individual animals in groups 2 and 4. As
shown in Figures 3 and 6, NHP7 (group 2) had detectable EBOV
RNA in the blood on day 6 and also had the highest IgG2/IgG1
Figure 3. Survival curve and clinical findings in rhesus macaques after EBOV challenge. Rhesus macaques were intramuscularly
challenged with 1000 PFU of EBOV on day 56 or 70 (challenge day 0). The Kaplan-Meier survival curve (A) indicates that 100% of animals immunized
with the replication-competent vaccine survived EBOV challenge. Clinical signs of infection such as body temperature (B), viremia (C), platelet count
(D), serum alanine aminotransferase (ALT) levels (E), and serum aspartate aminotransferase (AST) levels (F) were monitored daily.
doi:10.1371/journal.ppat.1003389.g003
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ratio of 1.6. The same is true for group 4 where both protected
animals had an IgG2/IgG1 ratio below 1.0, whereas the
unprotected animals were above 2.0. The only exception from
this observation is one protected animal in group 3 (NHP10),
which had a clear bias towards an IgG2 response indicated by an
IgG2/IgG1 of almost 3.0. However, this animal had a very low
antibody response even on day 6 after challenge (Figure 4). Lastly,
the final outcome at four weeks after challenge was similar for all
surviving animals with an IgG1-biased response and an IgG2/
IgG1 ratio of about 0.8 (similar to the positive control). In general,
this novel finding strongly indicates that an IgG1-biased immune
response against EBOV GP is advantageous for protection and
should be further evaluated with larger animal numbers and for
other vaccine approaches.
Lastly, qualitative antibody differences were also analyzed by
measuring the avidity of the antibodies before, during, and after
challenge in the vaccinated animals of groups 2–4. As shown in
figure 7 on day 42, the avidity of the antibodies in the serum of the
vaccinated animals was similar (group 2) or below that of the
control animals (group 3 and group 4). However, the avidity of
EBOV GP-specific antibodies significantly increased until chal-
lenge day 0 and was above the level of the control animals for most
of the vaccines, indicating that RABV-vector induced immune
responses mature over a long period of time. However, we did not
find a direct correlation between avidity of the EBOV GP-specific
antibody induced by the vaccines and protection from disease.
Two additional interesting findings are worth mentioning. As
listed above, it seems that the avidity of the EBOV GP-specific
Figure 4. Humoral immune response to EBOV GP after challenge. Rhesus macaque total IgG immune response to EBOV GP for post
challenge day 0 (A), day 3 (B), day 6 (C), day 16 (D), and day 28 (E). NHP responses were compared to the response of a control macaque which
survived EBOV infection. All sera were diluted 1:50 and analyzed in a 3 fold serial dilution via ELISA. NHPs belonging to Group 1, those immunized
with BNSP333, succumbed to EBOV infection by post challenge Day 9 whereas NHPs in (D) and (E) survived Ebola Zaire challenge.
doi:10.1371/journal.ppat.1003389.g004
Antibodies and Rabies/Ebola Vaccine Platform
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immune response is not complete until after day 42, since the
levels continue to increase at least until challenge day 0 (also
referred to as day 70), which is the last time point analyzed before
the challenge with EBOV (strain Mayinga). Secondly, and even
more interestingly, challenge with EBOV does increase the avidity
of the antibodies directed to EBOV GP (see Figure 7, challenge
Figure 5. Full length EBOV GP and EBOV GP-DMLD exhibit similar immunogenicity. Total IgG response to full length EBOV GP (A) and
EBOV GP-DMLD (B) on days 0, 3, and 6 post challenge.
doi:10.1371/journal.ppat.1003389.g005
Figure 6. IgG2/IgG1 isotype ratios in response to EBOV GP. (A) Isotype ratios (IgG2/IgG1) at 1:150 for post challenge days 0, 6, and 28. Ratios
less than 1.0 indicate a bias towards a Th1 response. Group 1 animals did not show an IgG1 or IgG2 response to EBOV GP so the ratios are not shown.
(B) Isotype ratios for protected animals versus unprotected animals after EBOV challenge. The isotype ratios of the protected animals were not
statistically significant when compared to the ratios of the unprotected animals. When analyzing the isotype ratios of group 2 and group 4 protected
animals to the unprotected animals in group 4, there is a significant difference (***, p,0.001). Statistical analysis was performed using unpaired t-test
with Welch’s correction to compare two groups. Results shown are presented as the mean. *p,0.05, **p,0.01, ***p,0.001.
doi:10.1371/journal.ppat.1003389.g006
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day 0 and post challenge day 3). In order to investigate if this is an
antigen-specific effect, we analyzed the avidity of the RABV G-
specific antibodies and observed a similar increase in avidity of the
RABV G-specific antibodies compared to EBOV GP-specific
antibodies, which was also confirmed by VNA (supplemental
Figure S1). The VNA showed a significant increase in the
surviving animals of about 3 to 4-fold. Even though we can only
speculate about the mechanism of protection, there is a clear
increase of the immune response even against an antigen (e.g.
RABV G) not expressed during the challenge virus infection.
Discussion
We have previously described the generation, propagation,
safety, immunogenicity, and protective efficacy of RABV/EBOV
vaccine candidates [18,36,37]. Two live vaccine candidates,
BNSP333-GP and BNSPDG-GP with a deletion of the entire
RABV G gene, were found to be avirulent upon peripheral
administration in mice. Based on the efficient incorporation of
EBOV GP into the virion, an inactivated vaccine (INAC-
BNSP333-GP) was also produced by treatment of the RABV/
EBOV vaccine with beta-propiolactone, the standard method
utilized for the current human RABV vaccine. Each bivalent
vaccine candidate induced strong humoral immunity to RABV G
and EBOV GP, and conferred protection from both lethal RABV
and mouse-adapted EBOV challenge in mice.
Based on the demonstration of promising safety, immunoge-
nicity, and protective efficacy of the live and inactivated RABV/
EBOV vaccines in mice, we sought to evaluate these vaccines in
nonhuman primates. All three vaccines did not induce any clinical
Figure 7. Avidity assay of total IgG immune response to EBOV GP. Sera were analyzed from day 42 (A), day 0 (challenge) (B), day 3 post
challenge (C), and day 28 post challenge (D) (study termination) with a NaSCN-displacement ELISA. Serum samples were diluted to an OD490 reading
of 0.8 based on total IgG ELISA data.
doi:10.1371/journal.ppat.1003389.g007
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sings including fever or weight loss after vaccination and we were
not able to detect any of the vaccine vectors in the blood of the
vaccinated NHP by RT-PCR (data not shown). However, further
safety studies are necessary for the replication-competent vector to
analyze any impact of EBOV GP for this vaccine. Immunogenicity
was examined following challenge with EBOV (strain Mayinga).
Each vaccine candidate was found to induce potent humoral
immunity and 50% to 100% protection from lethal challenge.
Our results indicate that the protection of immunized animals
was largely dependent on the induced humoral immune response
against EBOV GP. This finding is not too surprising because acute
viral infections are often controlled by antibodies rather than
cytotoxic T-cells, which in general are more important for the
control of chronic infections [38]. However, previous research did
suggest CD8+ T-cells as the major player for protection from
EBOV infection in a single vaccination strategy [13]. This has
been challenged by recent studies indicating that, in general,
protection of NHPs by different EBOV vaccines seems to depend
on the presence of anti-EBOV GP antibodies as well as EBOV
GP-specific CD4+ T-helper cells [9,12]. Moreover, it cannot be
excluded that CD8+ T-cells play a role in viral clearance but no
CD8+ memory T-cells are needed. Lastly, the relatively high
background in our ELISPOT assay might have prevented us to
detect low cellular responses. In any case, our results indicated a
major role of EBOV GP-specific antibodies to control the
challenge virus replication, and we therefore focused on these
responses in greater detail. In this regard, the finding that only
50% of NHPs in groups 3 and 4 were protected was an advantage,
because all three groups of vaccinated NHPs did have similar
levels of anti-EBOV GP antibodies as analyzed using an EBOV
GP-specific ELISA. This suggested a qualitative difference in the
humoral responses for the three vaccines.
First we investigated if the anti-EBOV GP antibodies were
directed against different regions within the glycoprotein. Previous
work by others indicates that antibodies directed against the MLD
within EBOV GP can enhance the infection with EBOV [34].
Therefore, we analyzed the anti-EBOV GP humoral responses
from all three vaccines utilizing full-length EBOV GP and EBOV
GP-DMLD. However, there was no significant difference in the
ELISA signal for each serum sample to the two versions of EBOV
GP, and we concluded that MLD-directed antibodies do not
explain the difference in the observed protection.
Secondly, we analyzed if we could detect differences in the
avidity of the antibodies for the three groups of vaccinees, but such
differences were not detected. Surprisingly, we found that the
avidity of the anti-EBOV GP-specific antibodies greatly increased
during challenge at a similar percentage for all tested sera.
Whereas we cannot explain this increase in antibody avidity, it was
transient and not specific to antibodies against EBOV GP, as the
avidity of RABV G-specific antibodies also increased.
It is well established that EBOV GP-specific antibodies induced
by different EBOV vaccine candidates may have no or only weak
VNA activity, but are still protective [8,9]. These findings indicate
that antibody-dependent cell-mediated cytotoxicity (ADCC) might
play a major role in protection from EBOV infection. Because
ADCC depends on IgG1 antibody responses, we analyzed the
total IgG response and also the IgG subtype responses (e.g. IgG1
and IgG2). Our results indicated that all protected animals,
independent of the group, had an IgG2/IgG1 ratio of ,0.8
whereas the unprotected animals had a higher ratio of ,2.5.
Interestingly, two animals from group 3 and group 4, NHP10 and
NHP13, transiently had the highest viral loads and also had IgG2/
IgG1 ratios that fell between those of unprotected and protected
animals. These results clearly indicate that the quality of the
antibodies in regard to the isotypes is very important for a
successful EBOV vaccine based on EBOV GP. However, the
protected animals from group 2 and 4 had also the highest total
antibody levels and therefore we conclude that in the case of a
rabies-based EBOV vaccine, high level of GP-specific antibodies
that are IgG1-bias are very likely to be significant as shown for
groups 2 and 4 in Figure 6B.
In summary, the results presented in this study clearly indicate
that the RABV-based vector induced an immune response
sufficient to protect from lethal EBOV infection. In the case of
replication-competent RABV vectors expressing EBOV GP, no
further improvements are necessary and such a vector could be
used to protect NHPs from EBOV in the endemic setting. Of note,
it would be best to establish efficacy via an oral application, which
is already well established for live RABV in wildlife [30,31]. The
replication-deficient and the inactivated RABV particles did not
protect all animals; therefore, the responses induced by these
vaccines need to be improved to resemble the responses detected
for the replication-competent vaccine, BNSP333-GP, which did
protect 100% of the animals. In any case, for the replication-
deficient vector, the virus could be concentrated so higher titers
such as the once used for the replication competent vaccine can be
used for the immunization. We cannot exclude the possibility that
using a five-fold lower titer for the immunizations than was used
for BNSP333-GP was responsible for this difference in protection.
Moreover, another vector choice could be the matrix protein
(M)-deleted replication-deficient RABV vector expressing EBOV
GP. Studies with such a vector as a RABV vaccine indicated that it
is superior, even compared to a replication-competent RABV
[39]. In the case of the inactivated virions containing EBOV GP, a
new construct containing an exact fusion of the RABV G
cytoplasmic domain to EBOV GP increased the incorporation
level about two-fold (the previous construct contained two foreign
amino acids between the EBOV GP transmembrane domain and
the RABV G cytoplasmic domain) and showed better responses
than the current construct in mice (Willet and Schnell, unpub-
lished data). Moreover, we discovered that the glycosylation
pattern of EBOV GP was different for RABV particles grown on
BSR cells than particles grown on VERO cells (data not shown).
Therefore, we believe that the utilization of particles containing
higher levels of EBOV GP and perhaps an additional immuni-
zation dose would bring the protection rate to 100% of the
animals, a reachable goal for a safe and promising dual vaccine.
Materials and Methods
Animal ethics statement
This study was carried out in strict accordance with the
recommendations described in the Guide for the Care and Use of
Laboratory Animals of the National Institute of Health, the Office
of Animal Welfare and the United States Department of
Agriculture. All animal work was approved by the NIAID Division
of Intramural Research Animal Care and Use Committees
(IACUC), in Bethesda, MD (protocol # OSD-28) and at the
Rocky Mountain Laboratories (RML, protocol # 2012-004-E).
Both facilities are accredited by the American Association for
Accreditation of Laboratory Animal Care. All procedures were
carried out under Ketamine anesthesia by trained personnel under
the supervision of veterinary staff and all efforts were made to
ameliorate the welfare and to minimize animal suffering in
accordance with the ‘‘Weatherall report for the use of non-human
primates’’ recommendations. Animals were housed in adjoining
individual primate cages allowing social interactions, under
controlled conditions of humidity, temperature and light (12-hour
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light/12-hour dark cycles). Food and water were available ad
libitum. Animals were monitored twice daily (pre- and post-
challenge) and fed commercial monkey chow, treats and fruit twice
daily by trained personnel. Early endpoint criteria, as specified by
the RML IACUC approved score parameters, were used to
determine when animals should be humanely euthanized.
NHP immunization and challenge
Fifteen RABV and EBOV seronegative rhesus macaques were
assigned to four groups to evaluate the recently developed RABV/
EBOV vaccine candidates (Figure 1). Groups of four animals were
used for the vaccine candidate groups while a group of three
animals served as the negative control. On day 0, group 1 (control)
animals were immunized intramuscularly (i.m.) in the caudal thigh
with a 56107 FFU dose of live parent RABV vaccine, BNSP333.
Group 2 animals were immunized i.m. with a 56107 FFU dose of
the full length parent RABV vaccine expressing EBOV GP
(designated as BNSP333-GP). Group 3 animals were immunized
i.m. with a 16107 dose of the parent vaccine expressing EBOV
GP but containing a deletion in the rabies glycoprotein gene
(designated BNSPDG-GP). Group 4 animals were immunized i.m.
with 250 mg of beta-propiolactone inactivated BNSP333-GP
(designated INAC-BNSP333-GP). Group 4 was boosted with
250 mg inactivated virus on day 28. All macaques were bled on
days 0, 1, 3, 5, 7, 14, 28, 35, and 42 before transport from the
National Institutes of Health Animal Center (Poolesville, MD) to
the National Institutes of Health, Rocky Mountain Laboratories
(Hamilton, MT). Since the challenge virus stock had never been
utilized in rhesus macaques, we infected two of the three control
animals (NHP1 and NHP2) on day 56 with 1000 PFU of EBOV
(strain Mayinga). Based on finding that the utilized virus was
virulent and caused EBOV hemorrhagic disease, we infected the
remaining 13 animals on day 70 with the same challenge virus
stock and dose. For each challenge experiment, physical exams
and blood draws were performed on day 0, 3, 6, 9, 12, 16, 22, and
28 post-challenge. Serum aliquots treated by gamma-irradiation as
per approved protocol were sent to Thomas Jefferson University
for analysis by enzyme-linked immunosorbent assay (ELISA).
Hematology and serum chemistries
The total white blood cell count, lymphocyte, platelet, reticulo-
cyte and red blood cell counts, hemoglobin, hematocrit values,
mean cell volume, mean corpuscular volume, and mean corpus-
cular hemoglobin concentrations were determined from EDTA
blood with the HemaVet 950FS+ laser-based hematology analyzer
(Drew Scientific, Waterbury, CT). Serum biochemistry was ana-
lyzed using the Piccolo Xpress Chemistry Analyzer and Piccolo
General Chemistry 13 Panel discs (Abaxis, Union City, CA).
Viral load
Levels of viral RNA were determined using quantitative RT-
PCR (qRT-PCR) as described previously [12]. For determination
of virus titers in NHP blood and tissue samples, Vero E6 cells were
seeded in 48-well plates the day before titration. Blood samples
were thawed and serial dilutions were prepared. Tissues were
homogenized in 1 ml plain DMEM and, as with the blood, serial
dilutions were prepared. Media was removed from cells and
triplicates were inoculated with each dilution. After one hour,
DMEM supplemented with 2% FBS, penicillin/streptomycin and
L-glutamine was added and incubated at 37uC. Cells were
monitored for cytopathic effect (CPE) and 50% tissue culture
infectious dose (TCID50) was calculated for each sample employ-
ing the Reed and Muench method.
ELISPOT
To evaluate T- cell responses to EBOV GP, NHP PBMCs were
tested using the NHP IFNc ELISPOT Kit (R&D Systems, Cat#
EL961) as per the manufacturer’s instructions. Briefly, microplates
were filled with 200 ml per well of sterile culture media (RPMI-
1640, 10% FBS, 1% Penstrep) as blocking media and incubated at
room temperature while NHP PBMCs and stimulating antigens
were prepared for plating. Antigens were prepared in sterile culture
media to achieve final concentrations as follows: GP peptide pool
(JPT) at 10 mg/ml; Pokeweed Mitogen (positive control) at 1 mg/
ml; Influenza NP peptide (Mimotopes, negative control) at 10 mg/
ml. Unstimulated cells were used to normalize spot counts to
background levels. Blocking media was removed, and antigen was
added respectively. PBMCs were added to respective wells at
16105 cells/well. Plates were incubated at 37uC, 5% CO2 for
48 h. Cells were then removed, and plates were washed four times
with Wash Buffer (R&D Systems). Plates were stained and
developed according to R&D Systems protocol with Detection
Antibody, Streptavidin-AP and BCIP/NBT chromogen. Plates
were rinsed with deionized water and allowed to dry completely
before scanning and counting using a CTL Immunospot Reader.
RABV VNA
A modified rapid fluorescent focus inhibition test (RFFIT) was
performed to determine RABV neutralizing antibody levels in the
immunized NHP sera. Three-fold serial dilutions of sera or WHO
standard RABV IgG in Cellgro Complete serum free media
(Mediatech) were incubated at 37C for 1 h with BNSP (parent
RABV of BNSP-333 that does not have the attenuating mutation
at position 333) at a concentration to achieve an moi of 1 at 24 h
post-infection in the negative control. Then, the mixture was
added to one day old BSR cells (BHK-21 derived cell line) that
had been grown in DMEM (Mediatech) supplemented with 10%
FBS (Atlanta Biologicals) and 1% penicillin/streptomycin (Med-
iatech) on 96 well plates, and plates were incubated for 24 h at
34C. Plates were then fixed with 80% acetone and stained with
anti-RV N (Fujirebio). Plates were read for percent infected cells
per well, and IUs of antibody were calculated based on the WHO
standard, where 50% infection accounts for 2 IU.
EBOV VNA
Neutralizing antibody titers were determined by performing
focus reduction neutralization titration assays (FRNT) as described
previously [12]. Briefly, Vero E6 cells were seeded into 96 well
plates to generate a confluent monolayer on the day of infection.
Serum dilutions were prepared in plain DMEM and 25 ml were
incubated with 200 ffu EBOV expressing green fluorescence
protein (EBOV-GFP) in a total volume of 50 ml. After 60 min at
37uC the media was removed from cells, the serum-virus mixture
was added and samples were incubated for 60 min at 37uC. Then
the mixture was removed from the cells and 100 ml of 1.2%
carboxymethyl cellulose in MEM (2% FBS) was added per well
and left for 4 days at 37uC. The neutralizing antibody titer of a
serum sample was considered positive at a dilution showing
a.80% reduction (FRNT 80) in GFP-foci compared to the
control without serum.
Production of HA-tagged EBOV GP
Sub-confluent T175 flasks of 293T cells (human kidney cell line)
were transfected with a hemagglutinin (HA) tagged EBOV GP
expression plasmid encoding amino acids 33–632 of the EBOV
GP ectodomain (EBOV GP-DTM) or a truncated version that
lacks amino acids 312–462 of the EBOV GP mucin-like domain
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(EBOV GP-DMLD-DTM). Both plasmids were kindly provided
by Erica O. Saphire of the Scripps Research Institute, La Jolla,
CA. Supernatant was added to an equilibrated anti-HA agarose
(Pierce) column containing a 2.5 mL agarose bed volume. The
column was washed with 10 bed volumes of TBST (TBS con-
taining 0.05% Tween 20) and 2 bed volumes of TBS before
adding 5 mL of 200 mg/mL HA peptide in TBS (Pierce HA
peptide). The peptide was added at a flow rate of 500 mL/min and
incubated overnight at 4uC. Bound EBOV GP was eluted with
3 mL of 200 mg/mL HA peptide in TBS. Fractions were collected
and analyzed for EBOV GP via Western blot with a nitrocellulose
membrane and monoclonal anti-HA antibody (Sigma) prepared in
5% BSA/TBST and goat anti-mouse IgG-HRP. EBOV GP posi-
tive fractions were dialyzed with 10K MWCO dialysis cassettes
(Thermo Scientific) to remove excess HA peptide used to elute the
HA-tagged EBOV protein.
Total IgG and isotype ELISAs specific for EBOV GP and
RABV G
Rhesus macaque sera obtained from the NIH were tested to
analyze the humoral response to EBOV GP and RABV G. EBOV
GP antigen for coating plates was obtained by harvesting super-
natant from transfected 293T cells and purifying the secreted
protein with an anti-HA agarose column as described above. 96-
well plates (Nunc, Immulon 4 HBX) were coated overnight at 4uC
with 50 ng/well purified EBOV GP or 100 ng/well purified
RABV G in Na2CO3 coating buffer. Plates were washed three
times with PBST (PBS with 0.025% Tween 20) and blocked at
room temperature for 1–2 hours with 5% dry non-fat milk in
PBST. Serum samples were diluted 1:50 in 0.5% BSA-PBST and
100 uL was added to each well in a 1:3 serial dilution. Plates were
incubated overnight at 4uC, washed three times with PBST, and
incubated for 2 hours with 100 uL/well of goat anti-human IgG-
HRP. Plates were washed with PBST and developed with 200 uL/
well of SigmaFast o-phenylenediamine dihydrochloride (OPD)
substrate. After incubating for 5 minutes at room temperature, the
reaction was stopped with 50 uL of 3 M H2SO4 and the
absorbance was read at 490 nm. IgG subclass specific ELISAs
were performed for EBOV GP and RABV G with anti-human
(Abcam) and anti-rhesus (NIH NHP Reagent Source) antibodies.
Plates were incubated with OPD substrate for 8–13 minutes
before stopping the reaction with 3 M H2SO4.
Antibody avidity assays
Macaque sera were measured for total IgG avidity to RABV G
and EBOV GP using a sodium thiocyanate (NaSCN) displacement
ELISA to determine the concentration of NaSCN needed to
dissociate 50% of the antibody-antigen interactions. The avidity
assays were set up similar to the ELISA protocol described above
however the sera samples were diluted to the concentration that
would yield an OD reading of 0.8 nm. Prior to incubation with the
secondary antibody, the plates were treated with increasing con-
centrations of NaSCN in PBS (0 M, 1 M, 2 M, 3 M, 4 M, 5 M, 6 M)
for 15 minutes at room temperature. Wells receiving 0 M NaSCN
were incubated with PBS. The plates were immediately washed three
times with PBST (0.025% Tween in PBS) before continuing with the
ELISA protocol. All avidity assays were performed in triplicate.
Statistical analysis
All data were analyzed by Prism software (GraphPad, version
5.0 d). Statistical analysis was performed using unpaired t-test with
Welch’s correction to compare two groups and represented as two-
tailed p-value with a confidence interval of 95%. Presented results
show the mean of measurements within a group. For all statistics,
the following notations are used to indicate significance between
two groups: *p,0.05, **p,0.01, ***p,0.001.
Supporting Information
Figure S1 Avidity of IgG antibodies in response to RABV
G and RABV G neutralization assay. Sera were analyzed on
day 28 (A) (INAC BNSP333-GP animals boosted), day 35 (B), day
42 (C), post challenge day 0 (D), day 16 (E), and day 28 (F) with a
NaSCN-displacement ELISA. Serum samples were diluted to an
OD490 reading of 0.8 nm based on total IgG ELISA data. (G)
Neutralization assay for RABV G post challenge.
(TIF)
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